Acting on Actionable Mutations: Genetic Testing and PARP Inhibitors for Advanced Prostate Cancer

Acting on Actionable Mutations: Genetic Testing and PARP Inhibitors for Advanced Prostate Cancer

Drs. Catherine Marshall, Melissa Reimers, and Tanya Dorff share their thoughts on ordering somatic versus germline testing for patients advanced prostate cancer, PARP inhibitor treatment strategies for BRCA-mutated patients throughout the care continuum, and treatment considerations for patients with other HRD pathway mutations.

ภาพตัวอย่างวิดีโอ
Acting on Actionable Mutations: Genetic Testing and PARP Inhibitors for Advanced Prostate Cancer
ภาพตัวอย่างวิดีโอ
How Do Genetic Mutations Impact Prostate Cancer Treatment Options?
ภาพตัวอย่างวิดีโอ
TALAVE: induction talazoparib with PARP inhibition in breast cancer
ภาพตัวอย่างวิดีโอ
Dr. Tanya Dorff on Incorporating mCRPC Prognostic Models Into Clinical Practice
ภาพตัวอย่างวิดีโอ
Real-world outcomes by co-mutation status in KRAS G12C-mutant NSCLC